Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide (LY3437943) in Chinese participants with overweight or obesity
NCT05548231Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing LY3437943 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 20 weeks. Started Oct 2022; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05548231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548231.